Study of DLBCL by genetic subtype
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how different genetic types of diffuse large B-cell lymphoma (DLBCL) respond to treatment in real-world settings. It may help doctors understand which treatments work best for your specific subtype.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL).
- Your lymphoma must have a specific genetic subtype (like MCD, BN2, EZB, or others from a gene test).
- You must agree to use reliable birth control if you could become pregnant or get someone pregnant.
- You cannot have severe mental illness that would interfere with the study.
- Your doctor must think you are suitable for the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This study looks at how certain blood tests (like CRP, albumin, and their ratios) might help predict how well treatment works for newly diagnosed DLBCL. If you are getting R-CHOP, this trial could help doctors better understand your response to therapy.
This study looks at whether blood tests for tumor DNA (cfDNA) can help guide treatment decisions for people with newly diagnosed DLBCL. It focuses on patients who achieve complete remission after 6 rounds of R-CHOP chemotherapy.
This trial tests a treatment plan that includes the drug tucidinostat for people who have not yet been treated for a type of lymphoma called DLBCL. It focuses on patients whose cancer cells have certain features (double expression of MYC and BCL2, or certain gene changes) that might affect how well standard treatments work.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.